PhytoHealth is a pharmaceutical firm dedicated to the creation of novel drugs that adhere to global standards and regulations. The company produces an injectable medication for cancer treatment and drugs that lower the risk of cardiovascular disease. Established in 1998, PhytoHealth is a part of Maywufa Biopharma Group.

Tags

Cardiovascular Diseases

Nervous System Diseases

Other Diseases

Small molecule drug

Herbal medicine

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Hemic and Lymphatic Diseases	2
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	3
Herbal medicine	2
Chemical drugs	1

Top 5 Target	Count

mAChRs(Muscarinic acetylcholine receptor)	1
TLR(Toll-like receptor)	1

Drugs associated with PhytoHealth Corp.

PG2

Target-

Mechanism

Immunostimulants

Active Org.

PhytoHealth Corp. [+1]

Originator Org.

Oxford PharmaGenesis Ltd.

Active Indication

Fatigue [+4]

Inactive Indication

Hemorrhagic stroke [+3]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date31 Dec 2004

Phencynonate

Target

mAChRs

Mechanism

mAChRs antagonists

Active Org.

PhytoHealth Corp.

Originator Org.

PhytoHealth Corp.

Active Indication

Motion Sickness

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date-

JKB-122

Target

TLR

Mechanism

TLR antagonists

Active Org.

PhytoHealth Corp. [+2]

Originator Org.

TaiwanJ Pharmaceuticals Co., Ltd.

Active Indication

Nonalcoholic Steatohepatitis

Inactive Indication

Crohn Disease [+4]

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with PhytoHealth Corp.

NCT05440227 / RecruitingPhase 2

A Phase II, Double Blind, Randomized, Placebo-controlled Study of PG2 Injection for the Treatment of moderate-to Severe Fatigue in Patients With Locally Advanced, Recurrent, or Metastatic Breast Cancer Who Are Receiving Infusional Chemotherapy

The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.

Start Date15 Jun 2022

Sponsor / Collaborator

PhytoHealth Corp.

NCT03611712 / Active, not recruitingPhase 2

PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer

The primary objective of this study is to evaluate the efficacy of PG2 concurrent with concurrent chemoradiation therapy (CCRT) for relieving fatigue among locally advanced esophageal cancer patients who are under preoperative chemoradiation therapy at curative setting. This study will be designed to compare the fatigue status between two study arms patients under CCRT.
The secondary objective is to assess the efficacy of PG2 to improve the quality of life of patient during CCRT. Also, the investigators try to determine the effect of PG2 on tumor response post CCRT, disease free survival (DFS) and overall survival (OS) of patients by comparing the above outcome between the two study arms.
The mechanism of immunomodulatory of PG2 and tumor response, DFS and OS for patients with esophageal cancer treated with preoperative CCRT concurrent with or without PG2 will be investigated in add-on study.

Start Date19 Feb 2019

Sponsor / Collaborator

PhytoHealth Corp.

NCT03314805 / CompletedPhase 2

PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence. Anthracycline-based regimens, including doxorubin or epilubicin, are the breast cancer adjuvant chemotherapy standards of care. Fatigue has also been identified as the most problem for breast cancer patients under adjuvant chemotherapy. In the current study, it is aimed to show that PG2 (astragalus polysaccharides) treatment among stage II/III breast patients under adjuvant EC regimen in reduction of chemotherapy-induced toxicity and encouraging compliance with chemotherapy.

Start Date01 Mar 2018

Sponsor / Collaborator

PhytoHealth Corp.

100 Clinical Results associated with PhytoHealth Corp.

0 Patents (Medical) associated with PhytoHealth Corp.

Literatures (Medical) associated with PhytoHealth Corp.

01 Jan 2023·Frontiers in nutrition

Potential antidepressant effects of a dietary supplement from Huáng qí and its complex in aged senescence-accelerated mouse prone-8 mice.

Article

Author: Li, Po-Hsien ; Chi, Ching-Hsin ; Huang, Mao-Jung ; Wong, Yue-Ching ; Huang, Ping-Hsiu ; Chou, Ming-Yu ; Wang, Teng-Hsu ; Wang, Ming-Fu ; Wang, Shih-Yi

Healthcare is an emerging industry with significant market potential in the 21st century. Therefore, this study aimed to evaluate the benefits of tube feeding Huáng qí and its complexes for 8 weeks on 3-month-old senescence-accelerated mouse prone-8 (SAMP8) mice, 48 in total, randomly divided into 3 groups including control, Huáng qí extract [820 mg/kg Body weight (BW)/day], and Huáng qí complexes (6.2 mL /kg BW/day), where each group consisted of males (n = 8) and females (n = 8). Behavioral tests (locomotion test and aging score assessment on week 6, the single-trial passive avoidance test on week 7, and the active shuttle avoidance test on week 8) were conducted to evaluate the ability of the mice to learn and remember. In addition, after sacrificing the animals, the blood and organs were measured for antioxidant and aging bioactivities, including malondialdehyde (MDA) content and superoxide dismutase (SOD) activity and catalase activities (CAT), and the effects on promoting aging in SAMP8 mice were investigated. The findings showed that Huáng qí enhanced locomotor performance and had anti-aging effects, with positive effects on health, learning, and memory in SAMP-8 mice (p < 0.05), whether applied as a single agent (820 mg/kg BW/day) or as a complex (6.2 mL/kg BW/day) (p < 0.05). Based on existing strengths, a more compelling platform for clinical validation of human clinical evidence will be established to enhance the development and value-added of astragalus-related products while meeting the diversified needs of the functional food market.

01 Apr 2020·Materials Science and Engineering: CQ2 · ENGINEERING & TECHNOLOGY

A study of the differentiation of stem cells from human exfoliated deciduous teeth on 3D silk fibroin scaffolds using static and dynamic culture paradigms

Q2 · ENGINEERING & TECHNOLOGY

Article

Author: Ko, Chih-Sheng ; Chen, Xiao-Wei ; Huang, Te-Yang ; Wang, Guo-Shou ; Su, Wen-Ta

Stem cells from human exfoliated deciduous teeth (SHED) are considered the best current source of human stem cells due to their ability to differentiate into multiple cell lineages. Dynamic co-culture systems can improve the culture environment, as they provide cells with signaling factors, extracellular matrixes, and cellular shear force, as well as enable the formation of heterotypic clusters. We seeded SHED in 3D silk fibroin porous scaffolds under static and dynamic cultures for 28 days, using the NIH3T3 cultivated medium as an induction agent. Many hepatospheres formed in these porous scaffolds, and cellular viability was shown to continually increase by MTT assays. Hepatic AFP and ALB gene expression, as well as glycogen storage, albumin secretion, and urea synthesis, were greater in cells in the 3D porous scaffold under a dynamic culture than in those cultured under 3D static culture and petri dish conditions. However, the 3D static culture is still superior to the traditional petri dish culture. The NIH3T3 cultivated medium can significantly induce hepatic differentiation of SHED, while the 3D dynamic culture system significantly enhances hepatic differentiation of SHED. This study provides alternative sources of hepatocytes for liver disease treatment.

19 Mar 2020·Current Stem Cell Research & TherapyQ4 · MEDICINE

Stem Cells from Human Exfoliated Deciduous Teeth: A Concise Review

Q4 · MEDICINE

Review

Author: Chen, Jen-Hao ; Su, Wen-Ta ; Ko, Chih-Sheng

Stem Cells from Human Exfoliated Deciduous Teeth (SHED) originate from the embryonic neural crest as ectodermal mesenchymal stem cells and are isolated from human deciduous teeth. SHED expresses the same cell markers as Embryonic Stem Cells (ESCs), such as OCT4 and NANOG, which make SHED to have a significant impact on clinical applications. SHED possess higher rates of proliferation, higher telomerase activity, increased cell population doubling, form sphere-like clusters, and possess immature and multi-differentiation capacity; such high plasticity makes SHED one of the most popular sources of stem cells for biomedical engineering. In this review, we describe the isolation and banking method, the current development of SHED in regenerative medicine and tissue engineering in vitro and in vivo.

News (Medical) associated with PhytoHealth Corp.

16 Sep 2024

·www.prnewswire.com

PhytoHealth Corporation announced a new clinical study results published at 2024 ESMO Congress: PG2 plus preoperative chemoradiotherapy improves survival in patients with locally advanced esophageal cancer

TAIPEI and BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- A groundbreaking study conducted by PhytoHealth Corporation, a leading provider of botanical medicine, has revealed that combining Astragalus Polysaccharides (PG2®Lyo. Injection) with standard concurrent chemoradiotherapy (CCRT) significantly improves survival rates for patients with advanced esophageal cancer. The study enrolled 38 patients with stage IIb to IIIb esophageal cancer. Participants were randomly assigned to receive either CCRT alone or CCRT combined with PG2, a proprietary extract of Astragalus membranaceus roots developed by PhytoHealth Corporation. Results showed that patients who received PG2 in addition to CCRT experienced significantly longer overall survival compared to those who received CCRT alone. Furthermore, the combination therapy resulted in a higher tumor objective response rate. The study also found that PG2 helped strengthen the immune system by modulating the tumor immune microenvironment (TIME) and enhancing the suppression of tumor growth. 'These findings offer a new hope for patients with esophageal cancer,'' said Dr. Wen-Chieh Huang, Chief of Division of Thoracic Surgery at Mackay Memorial Hospital, Taiwan and the Principal Investigator of the clinical trial for PG2, a drug for cancer-related fatigue (CRF) relief developed by PhytoHealth Corporation, Taiwan. "PG2 has the potential to become a valuable addition to the standard treatment regimen, and can achieve improved patient outcomes.'' The data will be presented as a poster at the prestigious 2024 ESMO Congress. [ESMO abstract link]. Dr. Huang noted that treatment options for esophageal cancer patients are relatively limited compared to those for other cancers. However, this study has shown that PG2 combination therapy can reduce inflammation markers in the blood, decrease the differentiation of macrophages towards the M2 type, and even help shrink tumors while improving survival rates. This represents a significant breakthrough in the treatment of esophageal cancer. Dr. Huang further added that esophageal cancer patients often face tremendous challenges during treatment, with many unable to complete their therapy. However, by incorporating CRF medication, most patients were able to regain their strength, complete the full courses of cancer treatment, and achieve the expected therapeutic effects. Esophageal cancer is a challenging disease with high recurrence rates and poor survival outcomes. PG2, previously established as a treatment for cancer-related fatigue (already approved by Taiwan Food and Drug Administration) has shown promise as a potential treatment enhancer. This latest discovery marks a significant advancement in the ongoing battle against this challenging cancer. About PhytoHealth Corporation PhytoHealth Corporation is a leader in the development and manufacturing of botanical medicine and natural health products based in Taiwan. With a focus on scientific research and innovation, PhytoHealth is committed to providing safe, effective, and high-quality products that support overall health and well-being. Contact: Alison [email protected] Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

100 Deals associated with PhytoHealth Corp.

100 Translational Medicine associated with PhytoHealth Corp.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 16 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

Phase 3 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Phencynonate ( mAChRs )	Motion Sickness More	Approved
PG2	Fatigue More	Approved
JKB-122 ( TLR )	Nonalcoholic Steatohepatitis More	Phase 3
PHN013	Purpura, Thrombocytopenic, Idiopathic More	Phase 2
PHN015	Hemorrhagic stroke More	Clinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis